Patents Assigned to AlderBio Holdings LLC
-
Patent number: 9890214Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for TNF-?. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-TNF-? antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-TNF-? antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-TNF-? antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with TNF-?.Type: GrantFiled: May 28, 2015Date of Patent: February 13, 2018Assignee: ALDERBIO HOLDINGS LLCInventors: Katie Anderson, Benjamin H. Dutzar, Anne Elisabeth Carvalho Jensen, Leon F. Garcia-Martinez, Ethan W. Ojala, John A. Latham
-
Patent number: 9884912Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: November 18, 2014Date of Patent: February 6, 2018Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson Anderson, Benjamin H. Dutzar, Ethan Wayne Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Patent number: 9884909Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: GrantFiled: March 15, 2013Date of Patent: February 6, 2018Assignee: ALDERBIO HOLDINGS LLCInventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne McNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Patent number: 9879074Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.Type: GrantFiled: May 29, 2015Date of Patent: January 30, 2018Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Patent number: 9873746Abstract: Methods are provided for the synthesis and secretion of recombinant proteins preferably large mammalian proteins or hetero-multimeric proteins at high levels and for prolonged time in polyploid, preferably diploid yeast. These methods use various mating competent yeast, including Pichia. In a preferred embodiment, a first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.Type: GrantFiled: March 24, 2011Date of Patent: January 23, 2018Assignees: KECK GRADUATE INSTITUTE, ALDERBIO HOLDINGS LLCInventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya Tolstrorukov
-
Patent number: 9855332Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.Type: GrantFiled: May 21, 2012Date of Patent: January 2, 2018Assignee: ALDERBIO HOLDINGS LLCInventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
-
Patent number: 9834603Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: April 30, 2015Date of Patent: December 5, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Ann Elisabeth Carvalho Jensen, Katie Olson Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Patent number: 9821057Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.Type: GrantFiled: March 30, 2015Date of Patent: November 21, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
-
Patent number: 9783603Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.Type: GrantFiled: July 21, 2015Date of Patent: October 10, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Andrew Lawrence Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
-
Patent number: 9783602Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: GrantFiled: December 1, 2011Date of Patent: October 10, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne McNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Patent number: 9783601Abstract: Monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents.Type: GrantFiled: December 1, 2011Date of Patent: October 10, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham
-
Patent number: 9775921Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.Type: GrantFiled: November 24, 2010Date of Patent: October 3, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T. L. Smith, Mark Litton, Randall Schatzman
-
Patent number: 9771421Abstract: Methods of treating anemia in chronic diseases where IL-6 is elevated using IL-6 antagonist antibodies are provided.Type: GrantFiled: January 23, 2015Date of Patent: September 26, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, John Latham, Brian R. Kovacevich, Jeffrey T. L. Smith
-
Patent number: 9765138Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.Type: GrantFiled: March 31, 2015Date of Patent: September 19, 2017Assignee: ALDERBIO HOLDINGS LLCInventor: Jeffrey T. L. Smith
-
Patent number: 9765321Abstract: Novel promoters which are derived from P. pastoris pastoris which are inducible or repressible under specific growth conditions are provided. These promoters are useful for regulating the expression of a desired structural gene, e.g., a mammalian polypeptide. Particularly preferred is the use of these novel promoters to regulate gene expression in polyploidal yeast such as diploidal P. pastoris produced by mating or spheroplast fusion.Type: GrantFiled: July 3, 2014Date of Patent: September 19, 2017Assignee: ALDERBIO HOLDINGS, LLCInventors: James M. Cregg, Ilya I. Tolstorukov
-
Patent number: 9745373Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: GrantFiled: May 21, 2012Date of Patent: August 29, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne Mcneill, Nicole M. Janson, Maria-Cristina Loomis
-
Patent number: 9738713Abstract: Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA).Type: GrantFiled: March 23, 2015Date of Patent: August 22, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, John A. Latham, Ethan W. Ojala, Corinne C. Akatsuka, Pei Fan, Jeffrey T. L. Smith, Benjamin H. Dutzar
-
Patent number: 9732150Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.Type: GrantFiled: March 14, 2014Date of Patent: August 15, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Andrew L. Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
-
Patent number: 9725509Abstract: The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.Type: GrantFiled: January 23, 2015Date of Patent: August 8, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith
-
Patent number: 9724410Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.Type: GrantFiled: November 24, 2010Date of Patent: August 8, 2017Assignee: ALDERBIO HOLDINGS LLCInventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman